OLD Mission Capital LLC purchased a new stake in GlaxoSmithKline plc (NYSE:GSK) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 134,656 shares of the pharmaceutical company’s stock, valued at approximately $4,776,000.
Several other institutional investors have also recently bought and sold shares of GSK. Two Sigma Advisers LP grew its stake in shares of GlaxoSmithKline by 55.5% in the 4th quarter. Two Sigma Advisers LP now owns 5,074,642 shares of the pharmaceutical company’s stock valued at $179,998,000 after buying an additional 1,811,400 shares during the period. Hotchkis & Wiley Capital Management LLC grew its stake in shares of GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after buying an additional 569,600 shares during the period. Point72 Asset Management L.P. grew its stake in shares of GlaxoSmithKline by 504.4% in the 3rd quarter. Point72 Asset Management L.P. now owns 604,419 shares of the pharmaceutical company’s stock valued at $24,539,000 after buying an additional 504,419 shares during the period. Two Sigma Investments LP grew its stake in shares of GlaxoSmithKline by 23.7% in the 4th quarter. Two Sigma Investments LP now owns 2,388,168 shares of the pharmaceutical company’s stock valued at $84,708,000 after buying an additional 457,276 shares during the period. Finally, Armistice Capital LLC purchased a new stake in shares of GlaxoSmithKline in the 4th quarter valued at approximately $14,614,000. 10.98% of the stock is owned by institutional investors and hedge funds.
GlaxoSmithKline plc (NYSE GSK) opened at $37.13 on Wednesday. The company has a current ratio of 0.60, a quick ratio of 0.39 and a debt-to-equity ratio of 4.09. The firm has a market cap of $93,350.70, a P/E ratio of 47.00, a P/E/G ratio of 2.28 and a beta of 0.95. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $44.53.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Investors of record on Friday, February 23rd will be given a dividend of $0.633 per share. The ex-dividend date of this dividend is Thursday, February 22nd. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.82%. This is a boost from GlaxoSmithKline’s previous quarterly dividend of $0.50. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 320.26%.
Several research firms have recently weighed in on GSK. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 price target for the company in a research note on Tuesday, March 6th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Kepler Capital Markets raised shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Friday, February 9th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Monday, January 29th. Finally, TheStreet cut shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. GlaxoSmithKline currently has an average rating of “Hold” and a consensus target price of $38.77.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.